How effective is siponimod in treating CIDP?

Siponimod is a novel selective sphingosine 1-phosphate (S1P) receptor modulator that has been approved for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. However, no precise information is currently available regarding the specific effects of siponimod in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), as the available published information focuses mainly on the treatment of multiple sclerosis. Although there are similarities between CIDP and multiple sclerosis, there are still differences. Therefore, the effect of siponimod in treating CIDP may need further clinical research to confirm.